{"brief_title": "Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)", "brief_summary": "The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic hepatitis C, who failed PEG-Intron plus Rebetol treatment in protocol P02370 (NCT00039871).", "condition": ["Chronic Hepatitis C", "Liver Fibrosis"], "intervention_type": ["Biological"], "intervention_name": ["peginterferon alfa-2b (SCH 54031)"], "description": ["0.5 \u00b5g/kg Weekly QW SC for 36 months"], "arm_group_label": ["PEG-Intron (peginterferon alfa-2b) 0.5 \u00b5g/kg Weekly (QW)"], "criteria": "Inclusion Criteria: - Age at entry in study P02370 (NCT00039871) 18-65 years; - Nonresponder to PEG-Intron plus Rebetol in study P02370 Exclusion Criteria: - Participants who did not participate in the P02370 study. - Any medical condition, including but not limited to decompensated liver disease, malignancy or substance abuse, that developed during the P02370 study which could interfere with the participant's participation in and completion of this study.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis C", "Fibrosis", "Hepatitis, Chronic", "Hepatitis C, Chronic", "Liver Cirrhosis", "Peginterferon alfa-2b", "Interferon-alpha"], "id": "NCT00049842"}